| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC1093 | SU11274 (PKI-SU11274) Featured | SU11274 is a selective Met inhibitor with IC50 of 10 nM. |
|
| DC7302 | SU14813 Featured | SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3). |
|
| DC7509 | SU1498 Featured | SU1498 is a selective inhibitor of the VEGFR2; inhibits Flk-1with an IC50 of value of 700 nM. |
|
| DC9781 | SU4312(NSC86429) Featured | SU4312(NSC86429) is a selective, cell-permeable inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively). |
|
| DC7508 | SU 5402 Featured | SU5402（SU-5402; SU5402） is potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively). |
|
| DC5079 | Orantinib (TSU-68) Featured | SU6668 has greatest potency against PDGFR autophosphorylation with Ki of 8 nM, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. |
|
| DC10271 | SUN11602 Featured | SUN11602 is a novel aniline compound, which mimics the neuroprotective mechanisms of basic fibroblast growth factor. |
|
| DC3145 | Sunitinib base Featured | Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. |
|
| DC3146 | Sunitinib malate Featured | Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. |
|
| DC7885 | NVP-TAE226 Featured | TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. |
|
| DC7057 | TAK-285 Featured | TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. |
|
| DC10523 | TAK-659 HCl Featured | TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM. |
|
| DC10065 | Takeda-6d Featured | Takeda-6d has potent inhibitory activity in both B-RAF with an IC50 of 7.0 nM and VEGFR2 with an IC50 of 2.2 nM. |
|
| DC7894 | Tandutinib(MLN518) | Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2. |
|
| DC12256 | TAS-115 mesylate (TAS-115 methanesulfonate) Featured | TAS-115 mesylate is a potent VEGFR and c-Met/HGFR kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. |
|
| DC8376 | TAS-301 Featured | TAS-301 is an inhibitor of smooth muscle cell migration and proliferation. |
|
| DC10300 | Tbid | tBID is a selective inhibitor of homeodomain–interacting protein kinase 2 (HIPK2) with an IC50 of 0.33 µM. |
|
| DC9586 | Telatinib Featured | Telatinib(Bay 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. |
|
| DC10044 | ONO4059 analog Featured | The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range. |
|
| DC7065 | Tivantinib (ARQ 197) Featured | Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. |
|
| DC5078 | Tivozanib(AV-951) Featured | Tivozanib (AV-951, KRN-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 0.21 nM/0.16 nM/0.24 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met EGFR and IGF-1R. |
|
| DC7329 | Toceranib(SU 11654; PHA 291639) Featured | Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. |
|
| DC8494 | Toceranib phosphate(SU 11654) Featured | Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. |
|
| DC8223 | TP-0903 Featured | TP-0903 is a a high-affinity Axl inhibitor with IC50 of 27 nM. |
|
| DC8557 | AG879 Featured | Tyrphostin AG 879 is a protein tyrosine kinase inhibitor with potent effects on TrkA. |
|
| DC10835 | UM164 Featured | UM-164 is a Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer. |
|
| DC9289 | UNC-2025 HCl Featured | UNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3. |
|
| DC7931 | UNC2025 Featured | UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3. |
|
| DC10127 | UNC569 Featured | UNC569 is a novel small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. |
|
| DC11073 | UniPR1331 | UniPR1331 (UniPR-1331) is a selective, orally available antagonist of Eph/ephrin interaction with pIC50 of 5.45, IC50 of 2.9 uM. |
|
